Rafferty Asset Management LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK

Rafferty Asset Management LLC trimmed its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 31.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,327 shares of the company’s stock after selling 16,131 shares during the period. Rafferty Asset Management LLC’s holdings in Stoke Therapeutics were worth $830,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Generali Investments Management Co LLC purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $41,000. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after acquiring an additional 5,427 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in Stoke Therapeutics by 33.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after acquiring an additional 2,384 shares in the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 3,978 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the sale, the general counsel owned 11,831 shares in the company, valued at approximately $381,904.68. The trade was a 25.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 13,430 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the completion of the sale, the director directly owned 49,124 shares in the company, valued at $1,585,231.48. This represents a 21.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Stock Up 2.4%

NASDAQ STOK opened at $35.48 on Friday. The firm has a market capitalization of $2.03 billion, a PE ratio of 52.96 and a beta of 1.07. The stock’s 50 day moving average is $32.19 and its 200 day moving average is $28.94. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $39.81.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wedbush upped their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, January 12th. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. HC Wainwright raised their price objective on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, UBS Group set a $50.00 target price on Stoke Therapeutics in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $39.25.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.